Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
Superinvestors holding TRVI, Q2 2026
1 superinvestor reports holding Trevi Therapeutics, Inc. on Form 13F, worth $28.8M in total. Weight is Trevi Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Viking Global InvestorsAndreas Halvorsen | 0.1% | 1,544,644 | $28.8M | Reduced−51.7% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of TRVI each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−51.7%)
Q4 2025
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−37.6%)
Q3 2025
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+232.4%)
Q2 2025
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−52.2%)
Q1 2025
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−26.6%)
Q3 2022
1 superinvestor holding at quarter end